JPWO2021113770A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021113770A5
JPWO2021113770A5 JP2022534164A JP2022534164A JPWO2021113770A5 JP WO2021113770 A5 JPWO2021113770 A5 JP WO2021113770A5 JP 2022534164 A JP2022534164 A JP 2022534164A JP 2022534164 A JP2022534164 A JP 2022534164A JP WO2021113770 A5 JPWO2021113770 A5 JP WO2021113770A5
Authority
JP
Japan
Prior art keywords
cell therapy
subject
tumor burden
threshold level
lymph node
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022534164A
Other languages
English (en)
Japanese (ja)
Other versions
JP7605840B2 (ja
JP2023504737A5 (https=
JP2023504737A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063486 external-priority patent/WO2021113770A1/en
Publication of JP2023504737A publication Critical patent/JP2023504737A/ja
Publication of JP2023504737A5 publication Critical patent/JP2023504737A5/ja
Publication of JPWO2021113770A5 publication Critical patent/JPWO2021113770A5/ja
Application granted granted Critical
Publication of JP7605840B2 publication Critical patent/JP7605840B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022534164A 2019-12-06 2020-12-04 B細胞性悪性疾患を処置するための細胞療法と関連する毒性および奏効に関係する方法 Active JP7605840B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945105P 2019-12-06 2019-12-06
US62/945,105 2019-12-06
PCT/US2020/063486 WO2021113770A1 (en) 2019-12-06 2020-12-04 Methods related to toxicity and response associated with cell therapy for treating b cell malignancies

Publications (4)

Publication Number Publication Date
JP2023504737A JP2023504737A (ja) 2023-02-06
JP2023504737A5 JP2023504737A5 (https=) 2023-12-18
JPWO2021113770A5 true JPWO2021113770A5 (https=) 2023-12-18
JP7605840B2 JP7605840B2 (ja) 2024-12-24

Family

ID=74046188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534164A Active JP7605840B2 (ja) 2019-12-06 2020-12-04 B細胞性悪性疾患を処置するための細胞療法と関連する毒性および奏効に関係する方法

Country Status (10)

Country Link
US (1) US20230053787A1 (https=)
EP (1) EP4070097A1 (https=)
JP (1) JP7605840B2 (https=)
KR (1) KR20220132527A (https=)
CN (1) CN115398231A (https=)
AU (1) AU2020395318A1 (https=)
BR (1) BR112022010310A2 (https=)
IL (1) IL293393A (https=)
MX (1) MX2022006715A (https=)
WO (1) WO2021113770A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230548A1 (en) * 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
KR20240122664A (ko) * 2023-02-03 2024-08-13 서울대학교산학협력단 혈액암 치료를 위한 키메라 항원 수용체(Chimeric Antigen Receptor) T 세포의 비임상 평가 방법

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2117571C3 (de) 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (https=) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
JPH065637Y2 (ja) 1988-02-12 1994-02-09 コーア株式会社 チップ部品
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
FR2688138B1 (fr) 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
CA2147466A1 (en) 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
ATE186235T1 (de) 1996-04-24 1999-11-15 Claude Fell Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut
WO1999018129A1 (en) 1997-10-02 1999-04-15 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
HK1041454B (en) 1998-12-24 2004-12-31 生物安全股份有限公司 Blood separation system particularly for concentrating hematopoietic stem cells
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CA2824167C (en) 2002-09-06 2018-09-25 Amgen Inc. Therapeutic human anti-il-1r1 monoclonal antibody
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
CA2570817A1 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
MX2007011218A (es) 2005-03-23 2007-10-17 Biosafe Sa Sistema integrado para colectar, procesar y transplantar subconjuntos de celulas, incluyendo celulas madre adultas para medicina regenerativa.
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
EP2680006A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Treatment for Amyotrophic Lateral Sclerosis
CA2682527C (en) 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
RS56844B1 (sr) 2007-12-11 2018-04-30 Univ North Carolina Chapel Hill Retrovirusni vektori sa modifikovanim polipurinskim nizom
AU2009209251B8 (en) 2008-01-28 2015-03-26 Medimmune Limited Stabilized Angiopoietin-2 antibodies and uses thereof
WO2009099553A2 (en) 2008-02-01 2009-08-13 The Regents Of The University Of California Use of kinase inhibitor in treatment of atherosclerosis
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP4032552B1 (en) 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
US20100190755A1 (en) 2008-09-19 2010-07-29 Paul Abato Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
HUE032754T2 (en) 2011-05-05 2017-10-30 Novartis Ag CSF-1R inhibitors for the treatment of brain tumors
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
KR102134932B1 (ko) 2011-11-11 2020-07-17 프레드 헛친슨 켄서 리서치 센터 암을 위한 사이클린 a1―표적화된 t―세포 면역요법
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
US20150119267A1 (en) 2012-04-16 2015-04-30 Sloan-Kettering Institute For Cancer Research Inhibition of colony stimulating factor-1 receptor signaling for the treatment of brain cancer
SG10201609210SA (en) 2012-05-03 2016-12-29 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
DE112012007250B4 (de) 2012-12-20 2024-10-24 Mitsubishi Electric Corp. Fahrzeuginterne Vorrichtung und Programm
EP2970905B1 (en) 2013-03-15 2019-10-16 Stemcell Technologies Inc. Compositions and methods for obtaining enriched mesenchymal stem cell cultures
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
AU2014268364A1 (en) 2013-05-24 2015-12-10 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
CN113354744A (zh) 2013-12-20 2021-09-07 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
DK3166968T3 (da) 2014-05-02 2021-12-06 Univ Pennsylvania Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
CN107109438B (zh) 2014-11-05 2021-09-03 朱诺治疗学股份有限公司 用于转导及细胞处理的方法
AU2016229201B2 (en) 2015-03-06 2021-01-28 The Board Of Regents Of The University Of Texas System Anti-LILRB antibodies and their use in detecting and treating cancer
MA45341A (fr) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells

Similar Documents

Publication Publication Date Title
US20250026821A1 (en) Anti-tgf-beta antibodies and their use
US20220332823A1 (en) Methods of treating cancer
CN104592388B (zh) 一种抗人Tim‑3的单克隆抗体的抗原结合部分
EP2556091B1 (en) Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2018525367A (ja) がんの治療における抗pd−1抗体および抗m−csf抗体の併用
JP6661019B2 (ja) イヌ抗cd20抗体
US9631024B2 (en) Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors
JPWO2019228266A5 (https=)
TW202318436A (zh) 用於預測細胞激素釋放症候群之多變量模型
CN109160949B (zh) 一种鼠抗人pd-1单克隆抗体及应用
JPWO2020113194A5 (https=)
US20250313855A1 (en) Chimeric antigen receptor t cell therapy
US20230054718A1 (en) Anti-galectin-9 antibody and uses thereof
US20250179168A1 (en) Materials and methods for treating stress-related disorders and cancer
EP3293271A1 (en) Marker and target as a diagnostic variable and target for therapy of metastatic cancer
AU2025202735A1 (en) Compositions and methods for treating extensive stage small cell lung cancer (es-sclc)
US20230212292A1 (en) Use of anti-pd-1 antibody in treating neuroendocrine tumors
US20220348660A1 (en) Methods for the treatment of adult t-cell leukemia/lymphoma
US20210353750A1 (en) Methods of Treating Cancer
CN113244386A (zh) 抗pd-1抗体在治疗肿瘤中的用途
JPWO2021113770A5 (https=)
WO2020086943A1 (en) Methods of treating cancer
WO2023019129A1 (en) Biomarkers for cd40 agonist therapy
US20210380942A1 (en) Methods and compositions for the treatment of cancer and infectious diseases
WO2024120484A1 (en) Antibodies against edil3 and methods of use thereof